Safety & monitoring
If you are going to use these compounds — or are weighing it — the single most protective thing you can do is get bloodwork and stay connected to a clinician. This page covers what to monitor, the organ systems most at risk, and the signs that mean stop now.
Bloodwork that actually matters
Get a baseline before starting anything, then monitor on a schedule and after stopping. Numbers trending the wrong way are a reason to stop, not push through.
AAS and oral compounds sharply lower HDL and raise LDL
Hypertension is common and compounds cardiovascular risk
Androgens raise red-cell mass; thick blood raises clot risk
Screen 17α-alkylated oral hepatotoxicity
Kidney function, glucose, electrolytes
Track suppression and recovery
GH, insulin and metabolic agents affect glucose
Baseline before androgen exposure
Cardiovascular risk
Long-term anabolic-androgenic steroid use is associated with reduced left-ventricular function and accelerated coronary atherosclerosis, and the burden rises with cumulative lifetime dose. This is the risk most likely to kill quietly. Monitor blood pressure and a full lipid panel; raised haematocrit adds clotting risk. PMID 28533317 ↗
Stimulant “fat burners” add tachycardia and hypertension on top — combining them with anabolic strain compounds the danger. PMID 15060505 ↗
Liver
17α-alkylated oral steroids resist liver breakdown and are associated with cholestatic injury; in rare cases oral AAS have caused fatal hepatic necrosis. Keep oral exposure limited, avoid stacking two orals, and monitor ALT/AST and bilirubin. Jaundice, dark urine, or right-upper-quadrant pain warrant stopping and urgent care. PMID 37948000 ↗
Suppression & recovery
Nearly all androgens suppress your own testosterone production; recovery is variable and, for some, prolonged. Recovery and fertility management belong with an endocrinologist rather than guesswork.
Insulin, GH and metabolic agents
Insulin and IGF-1 lower blood glucose through overlapping pathways; used together — or by anyone without continuous glucose monitoring and medical supervision — they can cause severe, potentially fatal hypoglycaemia. Confusion, sweating, shakiness, or loss of consciousness are emergencies. PMID 19198769 ↗
When to seek care
- Chest pain, breathlessness, or a very fast or irregular heartbeat
- Yellowing of the eyes or skin, dark urine, or severe abdominal pain
- Sudden severe headache, vision changes, or one-sided weakness or numbness
- Confusion, sweating, shakiness, or fainting (possible hypoglycaemia)
- Persistent high blood pressure, or a haematocrit above the lab's reference range
- Thoughts of self-harm, or a marked change in mood or aggression
Reducing harm, in general
- Fewer compounds, lower exposure, shorter duration — every addition adds risk that stacks.
- Never combine two 17α-alkylated orals; never stack stimulants; never mix anything with DNP.
- Get baseline bloodwork, repeat it, and act on the trend rather than pushing through bad numbers.
- Keep a clinician in the loop — an honest conversation with a doctor is harm reduction.
Every compound page carries its own monitoring section and citations — start with the database or check a combination.